4.6 Article

Association between follistatin-related protein 1 and the functional status of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

Journal

CHINESE MEDICAL JOURNAL
Volume 134, Issue 10, Pages 1168-1174

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CM9.0000000000001454

Keywords

Anti-neutrophil cytoplasmic antibody; Follistatin-like 1; Functional status; Vasculitis

Funding

  1. Yonsei University College of Medicine [6-2019-0184]
  2. Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health and Welfare, Republic of Korea [HI14C1324]

Ask authors/readers for more resources

The study showed that serum FSTL1 concentration is significantly correlated with health and inflammation indices in AAV patients, serving as a predictor of current functional status.
Background: Follistatin-like 1 (FSTL1) plays both pro-inflammatory and anti-inflammatory roles in the inflammatory processes. We investigated whether serum FSTL1 could predict the current anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)-specific indices. Methods: We randomly selected 74 patients with AAV from a prospective and observational cohort of Korean patients with AAV. Clinical and laboratory data and AAV-specific indices were recorded. FSTL1 concentration was determined using the stored sera. The lowest tertile of the short-form 36-item health survey (SF-36) was defined as the current low SF-36. The cutoffs of serum FSTL1 for the current low SF-36 physical component summary (PCS) and SF-36 mental component summary (MCS) were extrapolated by the receiver operator characteristic curve. Results: The median age was 62.5 years (55.4% were women). Serum FSTL1 was significantly correlated with SF-36 PCS (r = - 0.374), SF-36 MCS (r = -0.377), and C-reactive protein (CRP) (r = 0.307), but not with Birmingham vasculitis activity score (BVAS). In the multivariable linear regression analyses, BVAS, CRP, and serum FSTL1 were independently associated with the current SF-36 PCS (beta = -0.255, beta = -0.430, and beta = -0.266, respectively) and the current SF-36 MCS (beta = -0.234, beta =-0.229, and beta = -0.296, respectively). Patients with serum FSTL1 >= 779.8 pg/mL and those with serum FSTL1 >= 841.6 pg/mL exhibited a significantly higher risk of having the current low SF-36 PCS and SF-36 MCS than those without (relative risk 7.583 and 6.200, respectively). Conclusion: Serum FSTL1 could predict the current functional status in AAV patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available